Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial [Phase 3]
Adaptive Phase 3 trial assessing optimized COVID-19 vaccination schedules for immunocompromised individuals, including patients with HIV and…
-
FDA approval · 2025-10-02FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) by Janssen Biotech, Inc., resulting in a label update for its use.
-
FDA approval · 2025-10-02FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved Janssen's supplemental application for TALVEY (talquetamab), authorizing an update to the product labeling related to its i…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Multiple Myeloma Prognostic Indices
A completed clinical trial update examining prognostic indices for multiple myeloma to improve risk stratification in hematologic diseases.
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma [NA]
A clinical trial evaluating high-dose chemotherapy with granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-10-01EMA Authorised: Farydak (panobinostat lactate anhydrous) — pharmaand GmbH
The EMA authorised Farydak (panobinostat lactate anhydrous) for the treatment of multiple myeloma. The marketing authorization holder is pha…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma [NA]
ClinicalTrials.gov update on a study evaluating the feasibility and effects of exercise in patients with multiple myeloma; the trial status …
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab [Phase 2]
Phase II study of a daratumumab-based combination (daratumumab, clarithromycin, pomalidomide, dexamethasone) in multiple myeloma patients pr…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) [Phase 1, Phase 2]
The document describes a Phase 1/2 clinical trial evaluating autologous stem cell transplant (ASCT) in combination with the CAR-T therapy C-…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating CT0596 in relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is cu…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Limited-duration Teclistamab [Phase 2]
A Phase 2 trial evaluating a limited-duration dosing regimen of teclistamab for multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of JNJ-64407564 in Japanese participants with relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating pomalidomide, ixazomib, and dexamethasone with or without cyclophosphamide intensification in relapsed o…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy
A registry study tracking immune-related adverse events in cancer patients receiving immunotherapy. The study is not yet recruiting and is s…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating a combination of elotuzumab, daratumumab, iberdomide, and dexamethasone in relapsed multiple myelom…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Iceland Screens, Treats or Prevents Multiple Myeloma [NA]
The Iceland iStopMM trial (NCT03327597) investigates screening, treatment, or prevention strategies to reduce progression from Monoclonal Ga…
-
EMA approval · 2025-09-29EMA Authorised: Empliciti (Elotuzumab) — Bristol-Myers Squibb Pharma EEIG
EU authorities have authorised Empliciti (elotuzumab) for multiple myeloma.
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma [EARLY_Phase 1]
A Phase 1 clinical trial is evaluating a BCMA/GPRC5D-targeted CAR-T therapy for refractory multiple myeloma. The study is not yet recruiting…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Financial Difficulty in Patients With Blood Cancer
This clinical trial update notes the completion of a study evaluating financial difficulties experienced by patients with blood cancers, spe…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies [EARLY_Phase 1]
An early-phase trial evaluating Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before desensitization and allogeneic stem cell t…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment [NA]
A clinical study is evaluating the safety and effectiveness of BCMA-GPRC5D CAR-T in relapsed/refractory multiple myeloma after third-line or…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for Isa-Rd (isatuximab plus lenalidomide-dexamethasone) in frail and/or very elderly patients with newly diagn…
-
EMA approval · 2025-09-25EMA Authorised: Zoledronic acid Teva (zoledronic acid) — Teva B.V.
The EMA authorised Teva B.V.'s Zoledronic acid product for bone-related conditions and cancer-related bone disease. The active substance is …
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Biomarker for Infection Risk in CLL and MM
This update describes a biomarker study to assess infection risk in patients with multiple myeloma and chronic lymphocytic leukemia. The tri…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
This clinical trial aims to build a research infrastructure to understand and address disparities in outcomes for multiple myeloma.